Post-earnings recap
Reported
Mon, May 9, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Castle Biosciences reported a larger-than-expected loss per share, which contributed to a significant drop in its stock price by 9.36%. The lack of revenue details and guidance may raise concerns among investors about the company's performance and future outlook. Overall, the results suggest challenges that the company may need to address moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.97 | N/A | -45.86% |
| Revenue | N/A | N/A | N/A |
No transcript is on record for this earnings call, so the analysis is based solely on numerical results.